Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTx-758 in metastatic castration resistant prostate cancer
NCT01615120Phase 2Completed
- Sponsor
- GTx
- Start
- Aug 2012
- Primary completion
- Nov 2016
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GTx-758 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GTx. Started Aug 2012; status: completed.
02
Drugs
GTx-758
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01615120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01615120.